This invention provides novel erbB2-binding internalizing antibodies. Theantibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and,upon binding, are readily internalized into the cell bearing the c-erbB2marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached toone or more effector molecules are also provided.